Date: 2011-11-22
Type of information: Company acquisition
Acquired company: Lectus Therapeutics (UK)
Acquiring company: UCB (Belgium)
Amount: undisclosed
Terms: UCB has acquired Lectus Therapeutics’s key pharmaceutical assets today via a licence and acquisition agreement. The transaction involves the acquisition of all the company’s drug discovery and development programmes targeting ion channels for the treatment of a specific set of CNS indications (Central Nervous System). Under the terms of the agreement UCB will also gain exclusive worldwide rights to commercialise products discovered from the use of Lectus’s proprietary LEPTICS® technology for a number of further ion channel targets. The drug discovery and development programmes acquired by UCB centre on the use of Lectus’s proprietary LEPTICS® technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins.
Details: Lectus Therapeutics is specialising in the discovery and development of novel drugs for pain management and associated disorders. Lectus exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels, to develop novel ion channel modulators that have the potential to offer important clinical and economic advantages over existing therapies.
Related: CNS diseases
